Cochrane · systematic review · CD013232
Superoxide dismutase for bronchopulmonary dysplasia in preterm infants
Albertella, M, Gentyala, RR, Paraskevas, T, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
NeonatalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
6
No studies
3
Included studies
NR
No studies 3 · 33.3%Ungraded 0 · 0%Very low 6 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Superoxide dismutase (SOD) compared to placebo for preventing bronchopulmonary dysplasia (BPD) in preterm infants
Population: preterm infants at risk of developing BPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
BPD defined as an oxygen requirement at 28 days№ of participants: 302(1 RCT) Superoxide dismutase (SOD) vs placebo | RR 1.09 [0.94, 1.26] | NR | Very low Downgraded: risk of bias, imprecision |
BPD defined as oxygen at 36 weeks' postmenstrual age№ of participants: 335(2 RCTs) Superoxide dismutase (SOD) vs placebo | RR 0.96 [0.72, 1.29] | NR | Very low Downgraded: risk of bias, imprecision |
Neonatal mortality (i.e. within 28 days)№ of participants: 335(2 RCTs) Superoxide dismutase (SOD) vs placebo | RR 0.98 [0.57, 1.68] | NR | Very low Downgraded: risk of bias, imprecision |
Mortality prior to discharge№ of participants: 78(2 RCTs) Superoxide dismutase (SOD) vs placebo | RR 1.2 [0.53, 2.71] | NR | Very low Downgraded: risk of bias, imprecision |
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) Superoxide dismutase (SOD) vs placebo | no estimate extracted | NR | No studies |
Need for supplemental oxygen (days)№ of participants: 0 (0 RCTs) Superoxide dismutase (SOD) vs placebo | no estimate extracted | NR | No studies |
Retinopathy of prematurity№ of participants: 277(2 RCTs) Superoxide dismutase (SOD) vs placebo | RR 0.95 [0.78, 1.15] | NR | Very low Downgraded: risk of bias, imprecision |
Severe retinopathy of prematurity (stage II or greater)№ of participants: 244(1 RCT) Superoxide dismutase (SOD) vs placebo | RR 0.97 [0.57, 1.65] | NR | Very low Downgraded: risk of bias, imprecision |
Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs) Superoxide dismutase (SOD) vs placebo | no estimate extracted | NR | No studies |